Abstract
Hypertension is commonly associated with diabetes mellitus. The combination of hypertension with obesity and diabetes is a well recognized entity known as the metabolic syndrome, which shares a common pathophysiology of insulin resistance. The individual components of this syndrome act synergistically to substantially increase the risk of renal disease, stroke, coronary artery disease, and death. Hypertension increases both macrovascular and microvascular complications of diabetes such as neuropathy, nephropathy, coronary artery disease, stroke, and retinopathy. Hence there is a pressing need to achieve good control of hypertension to reduce such complications. Studies have been conducted to define target blood pressure in order to minimize such complications and also to decide on the type of drugs most likely to reduce complications/adverse events among diabetics. Along with the trusted and proven therapies to control blood pressure in diabetes, efforts should also be underway to define the hitherto unknown factors contributing to this problem and the ways to control them. There is also a need to prevent the development of diabetes among those predisposed to it and a defined approach needs to be established.
Keywords: Hypertension, diabetes mellitus, pharmacotherapy, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, systolic blood pressure, mean arterial pressure, cardiovascular disease
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Hypertension in Diabetes: Optimal Pharmacotherapy
Volume: 9 Issue: 2
Author(s): Abhishek Biswas, Alicia Alvarez and Debabrata Mukherjee
Affiliation:
Keywords: Hypertension, diabetes mellitus, pharmacotherapy, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, systolic blood pressure, mean arterial pressure, cardiovascular disease
Abstract: Hypertension is commonly associated with diabetes mellitus. The combination of hypertension with obesity and diabetes is a well recognized entity known as the metabolic syndrome, which shares a common pathophysiology of insulin resistance. The individual components of this syndrome act synergistically to substantially increase the risk of renal disease, stroke, coronary artery disease, and death. Hypertension increases both macrovascular and microvascular complications of diabetes such as neuropathy, nephropathy, coronary artery disease, stroke, and retinopathy. Hence there is a pressing need to achieve good control of hypertension to reduce such complications. Studies have been conducted to define target blood pressure in order to minimize such complications and also to decide on the type of drugs most likely to reduce complications/adverse events among diabetics. Along with the trusted and proven therapies to control blood pressure in diabetes, efforts should also be underway to define the hitherto unknown factors contributing to this problem and the ways to control them. There is also a need to prevent the development of diabetes among those predisposed to it and a defined approach needs to be established.
Export Options
About this article
Cite this article as:
Biswas Abhishek, Alvarez Alicia and Mukherjee Debabrata, Hypertension in Diabetes: Optimal Pharmacotherapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (2) . https://dx.doi.org/10.2174/187152511796196533
DOI https://dx.doi.org/10.2174/187152511796196533 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke
Cardiovascular & Hematological Disorders-Drug Targets Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide
Recent Patents on Drug Delivery & Formulation 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Molecularly Imprinted Polymers for Selective Solid-Phase Extraction of Verapamil from Biological Fluids and Human Urine
Current Pharmaceutical Analysis Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design